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Background: There are many prognostic scales that aim to predict functional outcome
following acute stroke. Despite considerable research interest, these scales have had
limited impact in routine clinical practice. This may be due to perceived problems with
internal validity (quality of research), as well as external validity (generalizability of results).
We set out to collate information on exemplar stroke prognosis scales, giving particular
attention to the scale content, derivation, and validation.
Methods: We performed a focused literature search, designed to return high profile
scales that use baseline clinical data to predict mortality or disability. We described
prognostic utility and collated information on the content, development and validation
of the tools. We critically appraised chosen scales based on the CHecklist for
critical Appraisal and data extraction for systematic Reviews of prediction Modeling
Studies (CHARMS).
Results: We chose 10 primary scales that met our inclusion criteria, six of which had
revised/modified versions. Most primary scales used 5 input variables (range: 4–13), with
substantial overlap in the variables included. All scales included age, eight included a
measure of stroke severity, while five scales incorporated pre-stroke level of function
(often using modified Rankin Scale), comorbidities and classification of stroke type.
Through our critical appraisal, we found issues relating to excluding patients with missing
data from derivation studies, and basing the selection of model variable on significance in
univariable analysis (in both cases noted for six studies). We identified separate external
validation studies for all primary scales but one, with a total of 60 validation studies.
Conclusions: Most acute stroke prognosis scales use similar variables to predict
long-term outcomes and most have reasonable prognostic accuracy. While not all
published scales followed best practice in development, most have been subsequently
validated. Lack of clinical uptake may relate more to practical application of scales
rather than validity. Impact studies are now necessary to investigate clinical usefulness
of existing scales.
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INTRODUCTION
Outcomes following a stroke event can range from full recovery,
through varying degrees of disability to death. Given the
subsequent need for intervention planning, resource use, and
lifestyle adjustments, predicting outcome following stroke is
of key interest and importance to patients, their families,
clinicians, and hospital administrators. Various tools exist to
assist in estimating stroke-related prognosis. For example, the
ABCD2 score uses clinical features to predict risk of stroke
following transient ischemic attack (TIA) (1). Although there are
criticisms of ABCD2, it is widely used and included in stroke
guidelines (2).
Scales for predicting acute stroke outcomes from baseline
features are also described in the scientific literature (3–5).
Often prognosis scales report mortality; however, given the
disabling nature of stroke, scales predicting death and/or longer-
term disability may be more useful in the stroke setting (6).
However, these prognostic scales have had limited clinical
traction and have not been incorporated into routine clinical
practice (3). There are many plausible reasons why these scales
have not been adopted by the stroke community (6). In an
acute setting, scales may be perceived as being too complex to
use or may require information that is not routinely available
(for example, sophisticated neuroimaging) (3). Clinicians may
moreover be concerned that scales are inherently too generic,
and may not provide insight over what the clinician can
conclude based on individual patient factors and clinical
gestalt (7).
For many scales, clinicians may simply not be convinced of
their utility or the rigor of the underpinning science. These
points can be addressed by describing the validity of the scales.
Issues with validity could relate to the methodological quality
of the initial derivation of the scale (internal validity) or the
generalizability of a scale to a real-world population (external
validity). Robust evidence of validity requires assessment of
the scale in cohorts independent of the population used
to derive that scale (8). However, In some areas of stroke
practice, for example rehabilitation, it has been demonstrated
that independent validation studies are lacking for many
scales (5).
Collating evidence around the quality of the research
that led to development of prognostic scales and also the
results of subsequent validation work could be useful for
various stakeholders. For clinicians it may convince of the
utility, or lack of utility, of certain tools; for researchers
it may point to common methodological limitations
that need to be addressed in future work and for policy
developers, if a certain tool has a more compelling
evidence base than others, then this scale may be preferred
in guidelines.
Previous reviews have reported that many stroke prognosis
scales have similar properties such as discrimination and
calibration. These reviews also highlight the limited evidence for
external validity of many commonly used stroke scales (9, 10).
Distinguishing an optimal prognostic tool may not be possible
based on psychometric properties alone and factors such as
feasibility and acceptability in the real world setting need to
be considered.
We sought to collate and appraise a selection of exemplar
published stroke scales, designed for use in acute care settings.
We used these as a platform to discuss methodological quality
of prognostic scale development, while also considering potential
barriers or facilitators to implementation of the scales in
clinical practice.
METHODS
We performed a focused review of the literature to find scales
predicting post-stroke mortality and/or function. Our approach
followed that used in a recent comparative efficacy review of
stroke scales (9). Rather than assess every tool that has ever been
used to make outcome predictions in stroke, we were interested
in examples of high profile prognostic scales. Although our
intention was not a comprehensive search, we followed, where
relevant, Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidance for designing and reporting
our study (11). For consistency in use of terminology, we have
referred to the prediction models as “scales,” and the calculated
outputs of models as “scores.”
Inclusion/Exclusion Criteria
We defined a scale as any tool that uses more than two
determinants to estimate the probability of a certain outcome.We
focused on scales with predominant clinical input variables that
can be applied without specialist resources or tests and to this end
we excluded scales that had more than two neuroimaging input
variables. We limited to ischemic or all cause (undifferentiated)
stroke scales, recognizing the differing natural progression of
ischemic and hemorrhagic strokes.
Search Strategy
Our focus was on scales that are well known in the stroke field
and so we adapted our search using an approach that has been
used in other focused stroke studies (12, 13). We limited our
search to 11 high profile, international journals, chosen based
on relevance to stroke and clinical impact, covering fields of
stroke, neurology, internal medicine, and geriatric medicine (a
full list of journals and the search strategy are included in
Supplementary Materials).
Searches were from inception to May 2018. Once we had
selected chosen scales we used PUBMED and Google Scholar
electronic search engines to find the initial development paper
and any potential validation papers. A single researcher (SS)
performed the search and screened the results We assessed
internal validity of the search results by screening title lists twice
(October 2015 and May 2018).
Data Extraction and Critical Appraisal
Two researchers (BD, SS) extracted data from selected studies,
using a pre-specified proforma. This included information on:
data source, study sample characteristics, predictor, and outcome
variables, procedures involved in model derivation, methods
of validation, measures of performance and presentation of
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results. Extracted data were comprehensively reviewed to inform
critical appraisal, a process in which all authors (BD, SS, TQ)
were involved.
The methodological assessment of prognostic scales is an
evolving landscape. Although there is no consensus preferred
approach to this, there are certain features common to most tools
that purport to assess validity of prognosis research. We based
our assessment on recommendations from the Critical Appraisal
and Data Extraction for Systematic Reviews of Prediction
Modeling Studies (CHARMS) checklist (14). Discrepancies in
assessment between researchers were discussed and resolved
through consensus.
Data Used for Scale Development
We assessed the representativeness of the sample from which
information was collected. Generalizability of a scale to a broader
patient population may be compromised when recruitment takes
place in a highly specific context or is limited to a relatively
homogeneous group; when multiple inclusion and exclusion
criteria are applied; and finally, when patients with missing data
are excluded from the study (complete-case analysis). The latter
presents itself as an issue, as it is uncommon for variable values
to be missing completely at random. Often this is related to other
predictors, the outcome, or even the value of that variable itself
(15). Therefore, patients with missing data are likely to form a
selective rather than random subsample of the initial baseline
cohort, and may substantially differ from those included in the
analysis (14, 16).
Scale Variables
For predictor and outcome variables, a particular concern was
whether they are precisely defined andmeasured in a way that can
be reproduced across different centers. It is recommended that
continuous data (e.g., age) are not categorized when introduced
to a model as a predictor (17, 18). Doing so is associated with loss
of information and power, and increases the risk of generating
inaccurate estimates and residual confounding. Finally, bias
may arise from lack of blinding to predictors when assessing
an outcome, or blinding to the outcome where predictors are
assessed retrospectively.
Scale Development Process
In this context, we assessed study sample size against the
number of candidate predictors being tested. For logistic
regression procedures, we considered a minimum of ten events
(number of patients with the less frequent outcome) per
variable to be sufficient (19, 20). Evaluating the selection
process of predictors for inclusion in scales presents a
challenge, as there is no agreed approach (21). There are
however certain practices that are consistently stated to increase
risk of bias. One is selecting predictors for inclusion in
multivariable analysis based on significance in univariable
analyses (22). This approach may lead to exclusion of predictors
that could be associated with the outcome after adjusting
for the effects of other factors. A data-driven approach to
variable selection may lead to model overfitting (23) and
forward selection techniques should be avoided in multivariable
modeling (24). Either a full model approach (all candidate
variables included in the model) or backwards elimination
(beginning with all candidate predictors, removing those
that do not satisfy a pre-specified statistical criterion) is
preferable (25).
Assessment of Scale Performance
We distinguished three levels of validation: apparent, internal
and external (26–28). In apparent validation, predictive ability is
assessed in the development set itself andmay give overoptimistic
performance estimates. With internal validation two approaches
are described, split-sample and cross-validation. These involve
randomly splitting the baseline sample into development and
assessment sets. In the split-sample technique, the population
is divided once, in cross-validation, the process of sample
division is repeated for consecutive fractions of subjects, thus
allowing for each participant to be included in the validation
set once. Here, a larger part of the baseline sample can be
used for model derivation, avoiding the considerable loss of
power associated with split sample approaches (14). The most
efficient method of internal validation is considered to be
bootstrapping, where samples are drawn with replacement from
the original dataset, replicating sampling from an underlying
population (26). The generated sample is of the same size as the
original dataset.
Importantly, even with use of internal validation techniques,
assessing a scale’s performance in the development cohort
is considered insufficient to confirm its value and general
applicability (27, 29), In view of this, we prioritized findings
from external validation studies. External data can differ from
derivation data in terms of when and where it was collected,
as well as by research group. Typically, an external dataset is
comparable to the original, however in some studies a model
is intentionally tested in a population characterized by different
clinical features.
Reviewing study results on predictive performance, we
focused on measures of discrimination and calibration, as these
properties are necessary (although not sufficient) to ensure
clinical usefulness of a prognostic scale (14, 27). Discrimination
relates to the ability of a model to accurately distinguish
between those who develop a certain outcome and those who
do not, and is commonly expressed as the area under the
receiver operating characteristic curve (AUROC) (30). To aid
interpretation of results, we applied to following AUROC cut-
off values: 1.00—perfect discrimination; 0.90 to 0.99—excellent;
0.80 to 0.89—good; 0.70 to 0.79—fair; 0.51 to 0.69—poor; 0.50—
of no value, equivalent to chance (31). Calibration refers to the
level of agreement between observed and predicted outcome
probabilities, with assessment preferably based on inspection
of calibration plots/curves (32). Graphical evaluation can be
accompanied by reporting results of the Hosmer-Lemeshow
test, assessing whether there is a significant difference between
observed and predicted outcomes. The test has however limited
power for detection of poor calibration, is oversensitive in large
samples, and does not allow to determine the direction of
miscalibration (33).
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RESULTS
Overview of Scale Content and Quality
Our search returned 3817 results. We found 10 primary scales
that met our inclusion criteria, six of which also had modified
versions published (Tables 1, 2). Scales used from four to thirteen
input variables, with a mode of five. There was considerable
overlap in the predictors used, including variables relating to
demographics, past medical history and the acute stroke event
(Table 3). The most commonly incorporated predictors were:
age (all ten scales), a measure of stroke severity (eight); pre-
stroke function, comorbidities and stroke subtype (each present
in five scales). Individual scale content, with scoring, is presented
in Table 4.
For seven scales the outcome of interest was a specified range
of scores on the modified Rankin Scale (mRS) (34–36). The scale
is a measure of functional outcome following stroke, ranging
from no symptoms (a score of zero) through increasing levels
of disability, to death (a score of six). Five scales focused on
mortality, while one scale aimed to predict recurrent stroke and
another length of hospital stay. Four scales predicted more than
one outcome.
Our critical appraisal of scales’ development process identified
potential sources of bias in each study, as well as issues related
to incompleteness of reporting for methods and results. Most
common limitations were around handling missing data and
model development. In relation to the former, in two studies it
was not clearly stated how missing data was handled. Six studies
used complete-case analysis, and the remaining two excluded
participants from analyses involving the particular variables they
had no data for. For model development, six studies selected
variables for multivariable modeling based on the univariable
significance (Table 5).
We present an overview of each scale, focusing on scale
content, development, validation, and where applicable any
modification to the scale. We summarize our critical appraisal
of derivation studies and discuss potential issues around
implementation of the scales in routine clinical practice.
Acute Stroke Registry and Analysis of
Lausanne (ASTRAL)
Scale Content and Development
The ASTRAL scale uses six input variables to predict unfavorable
functional outcome at 3 months (mRS>2): age, stroke severity
according to the National Institutes of Health Stroke Scale
(NIHSS) (37), time from symptom onset to admission, range
of visual fields, acute glucose, and level of consciousness (38).
Based on these variables, an integer score is assigned, from
zero with no upper limit. Higher scores are associated with a
greater probability of an unfavorable outcome. Through a logistic
regression procedure, the scale was developed in a sample of
1,633 ischemic stroke patients from the Acute Stroke Registry and
Analysis of Lausanne (39).
Scale Validation and Updating
Using a 2-fold cross-validation technique for internal validation,
the scale was found to have good discriminatory power,
AUROC:0.85 for prediction of mRS>2 at 3 months. The
derivation paper further described external validation of the
scale in two independent cohorts from Athens and Vienna (40,
41), reporting AUROC values of 0.94 and 0.77, respectively.
Calibration was assessed in all three cohorts based on Hosmer-
Lemeshow test and inspection of calibration plots, indicating a
good fit with the data.
The ASTRAL scale has been subsequently externally validated
by seven studies, with six assessing predictive value based on
AUROC estimates (42–48). Within these, ASTRAL was found
to have fair to good discriminatory power, with the exception
of one study, involving a Brazilian cohort (AUROC 0.67) (44).
These external validation studies used differing time points for
outcome assessment (up to 5 years post-stroke) and differing
outcomes, including mortality and symptomatic intracerebral
hemorrhage (sICH).
Critical Appraisal and Clinical Application
In the ASTRAL derivation study we found potential sources
of bias relating to participant selection, namely excluding all
patients with pre-stroke dependency and any missing data. In
addition, treatment effects were not accounted for. We also
noted that some issues relevant to scale development were
unclear: whether any method of blinding was used, the number
of candidate predictors (which allows to estimate whether the
sample size was sufficient), and finally whether there were
any significant baseline differences between the derivation and
validation cohorts.
Despite these concerns, evidence from validation studies
suggests that the predictive performance of ASTRAL is sufficient
for the clinical setting. The scale was designed with the
acute context in mind, and does not require sophisticated
diagnostic tests. Nonetheless, in some cases, estimating onset
to admission time may not be possible. Where all necessary
information is accessible, the ASTRAL offers an easily-
calculable score, with use aided by color-coded graphs to
assign a percentage probability of unfavorable outcome based
on clinical features. There is also a score calculator available
online (49).
Dense Artery, mRS, Age, Glucose,
Onset-to-Treatment, and NIHSS (DRAGON)
Scale Content and Development
The DRAGON scale incorporates the six variables in its
acronym, as well as early infarct signs on computed tomography
(CT). It was developed to predict functional outcome at 3
months in stroke patients treated with intravenous tissue
plasminogen activator (IV-tPA) (50). The outcome was
trichotomized according to mRS scores, where mRS 0–2 was
defined as “good outcome,” mRS 3–4 as “poor outcome”
and mRS 5–6 as “miserable outcome.” Scale scores range
from one to ten, with higher values associated with poorer
outcomes. The scale was derived in a single-center Finish
cohort of 1,319 ischemic stroke patients, using a logistic
regression procedure.
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TABLE 1 | Derivation study characteristics.
Scale Derivation dataset Location Recruitment
type
Enrolment dates Stroke type Exclusion criteria of note
ASTRAL Acute Stroke Registry and
Analysis of Lausanne
Switzerland Single-center Jan 2003 to Jul 2010 Ischemic Pre-stroke mRS > 2
DRAGON Bespoke cohort Finland Single-center 1995 to Sep 2010 Ischemic Basilar artery occlusions
FSV Stroke Outcome Study Canada Single-center 2001 to 2002 Ischemic,
hemorrhagic
iSCORE Registry of the Canadian
Stroke Network
Canada Multi-center Jul 2003 to Jun 2008 Ischemic
PLAN Registry of the Canadian
Stroke Network
Canada Multi-center Jul 2003 to Mar 2008 Ischemic Patients receiving IV-tPA
SNARL Endovascular registry Unclear Multi-center Sep 2009 to Jul 2011 Ischemic
SOAR Anglia Stroke and Heart
Clinical Network Database
United Kingdom Multi-center 1997 to 2010 Ischemic,
hemorrhagic
SPI Carotid ultrasound register United States Single-center Jan 1984 to Feb 1987 Ischemic Artificial heart valves, previous
cerebrovascular event
S-TPI NINDS 1 & 2,
ATLANTIS A & B, ECASS
2 cohorts
International Multi-center Jan 1991 to Jul 1998* Ischemic Multiple, related to primary
randomized control trials; minor
strokes
THRIVE MERCI, Multi MERCI
cohorts
International Multi-center May 2001 to Dec 2003; Jan
2004 to Jul 2006
Ischemic Multiple, related to primary
single-arm trials.
IV-tPA, intravenous tissue plasminogen activator; mRS, modified Rankin Scale.
*Combined recruitment period for all trials.
Scale Validation and Updating
On internal validation, using 1,000 bootstrap replications,
DRAGON was found to have an AUROC of 0.84 (95%CI:
0.80–0.87) for prediction of miserable outcome. A comparable
AUROC value was obtained through external validation,
performed by the authors in a cohort of 330 Swiss patients:
0.80 (95%CI: 0.74–0.86). Calibration was not assessed. DRAGON
has undergone subsequent external validation in ten studies
(42, 43, 46, 51–57), all of which concluded the scale performswell,
and (where assessed) had fair to good discriminatory power. In
majority of cases, the scale was used in a similar context and for
the same purpose as in the derivation study. However, one study
assessed prediction of sICH (42).
Recognizing the increasing use of magnetic resonance
imaging (MRI), the original DRAGON scale was adapted to
include MRI based variables (58). Namely, with all clinical
variables remaining unchanged, proximal middle cerebral artery
occlusion on MR angiography replaced hyperdense artery sign,
and the diffusion-weighted imaging Alberta Stroke Program
Early Computed Tomography Score (DWI ASPECTS) replaced
CT early infarct signs (59, 60). The scale was derived in a French
cohort of 228 patients treated with IV-tPA. Internal validation
was performed using a bootstrapping method. For prediction of
3-month mRS>2, MRI-DRAGONwas found to have an AUROC
of 0.83 (95%CI: 0.78–0.88). The scale was externally validated
in one subsequent study, where reported AUROC values for
prediction of poor and miserable outcome were 0.81 (95%CI:
0.75–0.87) and 0.89 (95%CI: 0.84–0.95), respectively (61).
Critical Appraisal and Clinical Application
We identified issues in the DRAGON derivation study. All
continuous candidate predictors were categorized. A complete-
case analysis approach was employed and discriminatory power
was only estimated for prediction of miserable outcome, while
calibration was not assessed at all. Moreover, it seemed unclear
whether any blinding method was applied for assigning mRS
scores, and there were no description of themultivariablemethod
for selection of final predictors.
In the context of clinical practice, DRAGON score should
be easy to calculate [online score calculator available (62)].
Again, estimating symptom onset-to-treatment time may not be
possible in some cases. There is potential for misinterpretation
of early infarct and hyperdense cerebral artery signs (63–65).
From this point of view, MRI-DRAGON appears a valuable
alternative. MRI has been found to be a more sensitive method
for ischemia detection than CT, and use of a semi-quantitative
assessment of lesions is likely to ensure higher reproducibility
(66). Importantly, based on results of validation studies, both
versions of the scale seem to have satisfactory predictive
ability, although evidence on performance of MRI-DRAGON is
still limited.
Five Simple Variables (FSV)
Scale Content and Development
The FSV scale incorporates two models for predicting functional
outcome at 6 months post-stroke (67–69). One is used for
good (mRS<3) or excellent (mRS<2) outcomes, and one for
prediction of a devastating outcome (mRS>4; FSVDEV). The
two models share four input variables: age, pre-stroke functional
status (Oxford Handicap Score) (70), ability to lift both arms
off the bed, and normal verbal response on the Glasgow Coma
Scale (71). The first model additionally includes ability to
walk unaided, while the FSVDEV incorporates stroke subtype.
Prediction scores created based on the models range from−5
to 5 for the positive outcomes, and 0 to 15 for the devastating
outcome. In both cases, a higher score is associated with a
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TABLE 2 | Derivation study participants, outcomes and scale discriminatory power.
Scale Baseline
sample size
Total sample used for model
derivation
(% of baseline sample)
Outcome Timepoint of
outcome
assessment
Number of patients
with outcome (%)
AUROC (95% CI)* for
apparent/internal
validation
ASTRAL 1,967 1,645 (84%) mRS 3–6 3 months 559 (34%) 0.85
DRAGON 1,529 1,319 (86%) mRS 0–2
mRS 3–4
mRS 5–6
3 months
3 months
3 months
798 (60%)
339 (26%)
182 (14%)
Not reported
Not reported
0.84 (0.80 – 0.87)
FSV 598 538 (90%) mRS 0–1
mRS 0–2
mRS 5–6
6 months
6 months
6 months
Not reported 0.86
0.89
0.87
iSCORE Not available 8,223 (n/a) Death
Death
1 month
1 year
1,004 (12.2%)
1,853 (22.5%)
0.85**
0.82**
PLAN 12,576 4,943 (39%) Death
Death
mRS 5–6
1 month
1 year
Discharge
569 (11.5%)
1,088 (22.0%)
735 (14.9%)
0.85 (0.84–0.87)
0.82 (0.81–0.84)
0.89 (0.87–0.90)
SNARL 556 511 (92%) mRS 0–2 3 months 186 (36.4%) 0.79 (0.75–0.83)
SOAR Not available 12,355 (n/a) Death
Death
LOS < 8 days
7 days
Inpatient
n/a
Not reported
Not reported
n/a
0.79 (0.78–0.80)
0.79 (0.78–0.80)
0.61 (0.60–0.62)
SPI 352 142 (40%) Stroke or
death
2 years 38 (27%) Not reported
S-TPI 2,184 2,131 (98%) mRS 0–1
mRS 5–6
3 months
3 months
773 (36%)
464 (22%)
0.79**
0.78**
THRIVE 305 Not reported mRS 0–2
Death
3 months
3 months
94 (n/a)
111 (n/a)
0.71**
Not reported
mRS, modified Rankin Scale; LOS, length of hospital stay.
*Where reported in derivation study.
**AUROC for model, not derived risk score.
TABLE 3 | Categories of input variables included in post-stroke prognostic scales.
Scale Age Sex Pre-stroke
functional status
Comorbidity Time from
symptom
onset
Acute
physiology
Stroke
severity
Stroke
classification
Imaging
findings
Treatment
Astral
Dragon
FSV
iScore
PLAN
SNARL
SOAR
SPI
S-TPI
THRIVE
Green fill denotes inclusion of a variable from the given category in a prognostic scale.
greater likelihood of having the outcome of interest. Both FSV
models were derived in a single-center Canadian cohort of 538
stroke patients.
Scale Validation and Updating
Internal validation of the prediction scores, using 500 bootstrap
replications, indicated good discriminatory power, with AUROC
values of 0.88, 0.87, and 0.86 for good, excellent and devastating
outcomes, respectively. Similar results were reported for initial
external validation, conducted in a sample of patients from the
Oxfordshire Community Stroke Project (OCSP), with AUROC
values ranging from 0.86 to 0.89. Calibration was assessed only in
the derivation sample for prediction of good outcome, and, based
plotted calibration curves, concluded to be good (67).
FSV scores have been externally validated in one study (72),
reporting good discriminatory power for prediction of good
and devastating outcomes at 6 months in a Scottish stroke
cohort. The use of five variables for predicting post-stroke
functional outcome was also assessed in a cohort combining six
European populations. However, here a similar scale was being
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TABLE 4 | Scale variables and scoring systems.
Scale Variable Level/category Score
ASTRAL Acute glucose <3.7 or >7.3
mmol/L
1
Age Per every 5 years 1
Any stroke-related visual field
defect
Yes 2
Level of consciousness Decreased 3
Symptom onset to treatment
time
>3 hours 2
Stroke severity (NIHSS) Per every point 1
DRAGON Hyperdense cerebral artery or
early infarct signs on CT scan
None
Either
0
1
Both 2
Pre-stroke functioning (mRS) ≤1
>1
0
1
Age <65 years 0
65–79 years 1
>79 years 2
Acute glucose ≤8 mmol/L
>8 mmol/L
0
1
Symptom onset to treatment
time
≤90min
>90min
0
1
Stroke severity (NIHSS) 0–4 0
5–9 1
10–15 2
>15 3
FSV Able to lift both arms Yes 2
Able to walk unaided Yes 1
Age <80 years 1
Verbal GCS Normal 1
Pre-stroke functioning (mRS) Per every level −1
FSVDEV Able to lift both arms No 2
Age ≥80 years 3
Verbal GCS Abnormal 3
Pre-stroke functioning (mRS) Per every level 1
Stroke subtype classification
(OCSP)
TACS 2
iSCORE;
1-month
outcome
Age Per every year 1
Sex Male 10
Stroke severity (CNS) 0 105
≤4 65
5-7 40
>8 0
Stroke subtype (TOAST) Lacunar 0
Non-lacunar 30
Undetermined 35
History of atrial fibrillation Yes 10
History of congestive heart failure Yes 10
Cancer Yes 10
Renal dialysis Yes 35
Pre-stroke functioning Dependent 15
(Continued)
TABLE 4 | Continued
Scale Variable Level/category Score
Acute glucose ≥7.5 mmol/L 15
iSCORE;
1-year
outcome
Age Per every year 1
Sex Male 5
Stroke severity (CNS) 0 70
≤4 40
5-7 25
>8 0
Stroke subtype (TOAST) Lacunar 0
Non-lacunar 15
Undetermined 20
History of atrial fibrillation Yes 5
History of congestive heart failure Yes 10
Previous myocardial infarction Yes 5
Current smoker Yes 5
Cancer Yes 15
Renal dialysis Yes 40
Pre-stroke functioning Dependent 20
Acute glucose ≥7.5 mmol/L 10
PLAN Pre-stroke functioning Dependent 1.5
Cancer Yes 1.5
History of congestive heart failure Yes 1.0
History of atrial fibrillation Yes 1.0
Level of consciousness Reduced 5.0
Age Per decade 1.0
Arm weakness Significant/total 2.0
Leg weakness Significant/total 2.0
Neglect or aphasia Either/both 1.0
SNARL Symptomatic hemorrhage No 2
Stroke severity (NIHSS) >20 0
10–20 1
<10 3
Age >80 years 0
60–79 years 1
<60 years 2
Reperfusion (TICI) ≥2b 3
Location of occlusion M2 or distal 1
SOAR Age ≤65 0
66–85 1
SNARL >85 2
Stroke type Hemorrhagic 1
Stroke subtype classification
(OCSP)
LACS 0
PACS 0
POCS 1
TACS 2
Pre-stroke functioning (mRS) ≤2 0
3–4 1
5 2
SPI Age >65 3
Diabetes mellitus Yes 3
(Continued)
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TABLE 4 | Continued
Scale Variable Level/category Score
Acute severe hypertension Yes 2
Type of cerebrovascular event TIA 0
Stroke 2
History of coronary heart disease Yes 1
S-TPI; Good
outcome
IV-tPA treatment Yes N/a*
Age Per every year N/a*
Acute systolic blood pressure Per every 1 mmHg N/a*
Diabetes Yes N/a*
Sex Male N/a*
Stroke severity (NIHSS) Per every point N/a*
Previous stroke Yes N/a*
Symptom onset to treatment
time
Per every minute N/a*
Treatment × systolic blood
pressure
N/a*
Treatment × sex N/a*
Treatment × previous stroke N/a*
Treatment× symptom onset to
treatment time
N/a*
Age × stroke severity N/a*
S-TPI; Poor
outcome
Age Per every year N/a*
Stroke severity (NIHSS) Per every point N/a*
Acute glucose Per every mmol/L N/a*
ASPECTS score** Per every point N/a*
THRIVE Age ≤59 0
60–79 1
≥80 2
Stroke severity (NIHSS) ≤10 0
11–20 2
≥80 4
Diabetes mellitus Yes 1
History of hypertension Yes 1
History of atrial fibrillation Yes 1
ASPECTS, Alberta Stroke Program Early Computed Tomography Score; CNS, Canadian
Neurological Scale; CT, computed tomography; GCS, Glasgow Coma Scale; IV-tPA,
intravenous tissue plasminogen activator; LACS, lacunar stroke syndrome; mRS, modified
Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OCSP, Oxfordshire
Community Stroke Project; PACS, partial anterior circulation stroke syndrome; POCS,
posterior circulation stroke syndrome; TACS, total anterior circulation stroke syndrome;
TIA, transient ischemic attack; TICI, Thrombolysis In Cerebral Ischemia; TOAST, Trial of
ORG 10172 in Acute Stroke Treatment.
*Risk score was not developed.
**Optional variable.
independently developed rather than the FSV being externally
validated (73). The described model included the same variables,
although a different measure was used for estimating pre-stroke
functional status [Barthel index (74)]. The authors reported good
discriminatory power on both internal and external validation.
Critical Appraisal and Clinical Application
To assess FSV derivation, we reviewed three publications
and identified potential sources of bias. The sample size was
insufficient for the number of tested candidate predictors.
Although a complete-case analysis method was not applied,
with no data imputation, participants with missing data were
excluded from particular analyses. Blinding was unclear. Input
variables for multivariable analyses were selected based on
univariate significance. In the paper where models for excellent
and devastating outcomes were developed, calibration was
not assessed, while in the remaining two, the procedure was
mentioned but no calibration plots were presented. In relation
to study results, differences in baseline characteristics between
derivation and validation datasets were not assessed, and a data-
driven approach was applied when selecting cut-off scores for
outcome prediction (75).
In clinical practice, a significant advantage of FSV is the use
of easily accessible and often routinely collected information.
Moreover, for patients and their families, the differentiation
between recovering to a level of functional independence with
and without disability can be of particular value. It is unlikely
however for this useful concept to be transferred into practice,
as the same FSV cut-off score was chosen for both outcomes,
the difference lying in prognostic accuracy for prediction of each.
Finally, although reports on FSV performance are encouraging,
further external validation studies are necessary before it can be
considered for use in a clinical setting.
iScore
Scale Content and Development
The iScore was developed using a logistic regression procedure
to predict death at two timepoints. The derivation study
included 12,262 ischemic stroke patients from the Registry of
the Canadian Stroke Network (76). For outcome prediction
at 3 months, an integer score (from zero, with no defined
upper limit) is calculated based on: age, sex, stroke severity
assessed with the Canadian Neurological Scale (77), stroke
subtype according to the Trial of ORG 10172 in Acute
Stroke Treatment (TOAST) (78), acute glucose, history of atrial
fibrillation, congestive heart failure, cancer, kidney disease, and
preadmission dependency. For predicting one-year mortality,
previous myocardial infarction and smoking status are added.
Higher scores associated with greater mortality.
Scale Validation and Updating
In the derivation study, a split-sample validation method was
chosen, with 8223 patients assigned to the development set
(AUROC: 0.85 and 0.82 for 30-day and 1-year mortality,
respectively) and 4039 in the internal validation (AUROC: 0.85
and 0.84). External validation used data from 3270 patients from
the Ontario Stroke Audit. AUROC: 0.79 and 0.78, for 30-day and
1-year mortality, respectively.
The scale has been further externally validated in 15 studies
(48, 54, 79–91). The iScore has been applied not only to predict
mortality, but also poor functional outcome, institutionalization,
clinical response, hemorrhagic transformations following
thrombolytic therapy, and healthcare costs. All studies concluded
that iScore is useful, predicting outcomes of interest with
sufficient accuracy. Where AUROC values were estimated, they
were fair to good, apart from one study where AUROC was 0.68
for 30-day mortality or disability at discharge (79).
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TABLE 5 | Assessment of risk of bias in scale derivation studies.
Scale Data source Participants Outcome Predictors Sample size Missing data Model development Model performance Model evaluation Results
Astral
Dragon
FSV
iScore
PLAN
SNARL
SOAR
SPI
S-TPI
THRIVE
Color code: green, low risk of bias; yellow, unclear or medium risk of bias; red, high risk of bias.
Recognizing the difficulty of etiological classification (92), a
revised iScore (iScore-r) was developed, replacing TOAST with
OCSP (93). The revised scale was validated in a Taiwanese
cohort of 3,504 ischemic stroke patients, for prediction of poor
functional outcome (mRS>2) at discharge and at 3-months.
Assessment of discriminatory power in an external cohort of
iScore and iScore-r indicated comparable performance of the
scales. AUROC of 0.78 and 0.77 for discharge outcome, and
AUROC of 0.81 and 0.80 for 3-month outcome, with lower values
reported for iScore-r.
Critical Appraisal and Clinical Application
We identified limitations in the iScore derivation. A complete-
case analysis approach was applied. Variables were selected based
on univariable significance. Administration of treatments was
not accounted for. A split-sample method was used for internal
validation, while the external validation cohort was partially
recruited from the same centers as the derivation cohort, which
gives overoptimistic estimates of performance in independent
populations. It was unclear whether blinding was applied; which
inputs were included in the model as continuous and which
were categorized; and how pre-stroke dementia (a candidate
predictor) and dependency were operationalized.
The iScore scale has many external validation studies, which
indicate sufficient prognostic ability for outcomes other than
just mortality. Use of the scale can be aided by an online score
calculator (94). Nonetheless, compared to most scales included
in this review iScore require substantial baseline information.
The revised scale may offer a solution to the issues of acute
classification, yet the iScore-r derivation study reported high
attrition rates, and with no further external validation studies, the
generalizability of the scale remains uncertain.
Preadmission Comorbidities, Level of
Consciousness, Age, and Neurological
Deficit (PLAN)
Scale Content and Development
The PLAN scale was developed to estimate probability of death
and severe disability following ischemic stroke, specifically 30-
day and 1-year mortality, and mRS>4 at discharge (95). A risk
score ranging from 0-25 is calculated based on: pre-admission
dependency, history of cancer, congestive heart failure, atrial
fibrillation, consciousness, age, proximal weakness of the leg,
weakness of the arm, aphasia and neglect. Higher scores are
associated with greater likelihood of death or severe disability.
The scale was derived through logistic regression using the same
multicenter data source as in the case of iScore. The baseline
sample comprised 9,847 patients. However, as a split-sample
validation method was applied, only 4,943 of subjects were
included in the development set.
Scale Validation and Updating
The derivation study reported results of both apparent and
internal validation, with AUROC values ranging from 0.82 to
0.89 for all three outcomes. The scale’s performance was not
assessed in an independent dataset. External validation was
however conducted in two subsequent studies (48, 73). The scale
was applied for prediction of good functional outcome, poor
outcome, and mortality. In all analyses, PLAN was found to have
AUROC values above 0.80.
Critical Appraisal and Clinical Application
Our assessment of PLAN revealed issues predominantly related
to three aspects of scale development: predictors, the model
derivation procedure, and assessment of performance. In relation
to predictors, all originally continuous variables were categorized.
There was also a lack of reporting on how pre-stroke dementia
and dependency were operationalized, as well as on blinding
to outcome for assessment of input variables. In terms of
creating the model, variables for multivariable analysis were
chosen based on estimated associations in univariable analysis,
while the method for selecting final predictors in multivariable
analysis seemed unclear. Finally, the scale was only internally
validated, using a split-sample method. Calibration was assessed
alongside discrimination, however this was limited to performing
the Hosmer-Lemeshow test and correlations between observed
and expected outcomes. An additional concern is the lack of
statement on the method of handling missing data.
Given the increasing use of IV-tPA as a treatment option
in ischemic stroke, it is noteworthy that patients receiving this
intervention were excluded from the PLAN derivation study.
This does not necessarily entail limited applicability of the scale,
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particularly as the external validation studies, reporting good
performance for PLAN, both included IV-tPA-treated patients.
However, as the scale was only applied in two independent
dataset, it seems that more evidence is necessary before reaching
conclusions on PLAN’s generalizability. If an acceptable level
of performance is consistently indicated, another issue worth
investigating will be whether the relative complexity in scoring
impedes implementation of the scale in clinical practice.
Symptomatic Hemorrhage, Baseline
NIHSS, Age, Reperfusion, and Location of
Clot (SNARL)
Scale Content and Development
The SNARL scale uses the three clinical and two imaging
variables in its acronym to predict a good outcome (mRS<3) at
3 months following ischemic stroke treated with endovascular
therapy (96). Scores can range from zero to eleven, with higher
scores associated with a greater probability of a good outcome.
The scale was derived through a logistic regression procedure,
using data of 511 patients from a multicenter registry.
Scale Validation and Updating
Based on results of apparent validation, reported AUROC was
0.79 (95%CI: 0.75–0.83). The study also assessed the scale’s
performance in an independent cohort, comprising 223 patients
from the North American Solitaire Acute Stroke registry. For this
dataset, AUROC was 0.74 (95%CI: 0.68–0.81). In addition, the
authors reported that compared to the THRIVE scale (described
below), SNARL presented a 35% improvement in terms of
accurately classifying patients’ probability of a good outcome.We
did not identify any further external validation studies assessing
this scale.
Critical Appraisal and Clinical Application
Through our critical appraisal of the SNARL derivation study we
identified two sources of bias, both common across the reviewed
scales, use of a complete-case analysis approach and selection
of predictors based on associations in a univariable statistical
procedure. The applied input selection process in multivariable
analysis, on the other hand, seemed unclear, as did the use
of any blinding methods. Finally, although predictors were
well-operationalized, interpretation of imaging findings may be
subject to relatively high interobserver variability.
Stroke Subtype, OCSP, Age, and
Pre-stroke mRS (SOAR)
Scale Content and Development
SOAR was developed to predict early mortality (inpatient and
7-day) and length of hospital stay, based on the four clinical
variables of the scale’s acronym (97). Using a logistic regression
model, a scoring system ranging from 0 to 8 was derived, with
higher scores associated with a greater likelihood of death and
extended length of stay. The derivation cohort included 12,355
acute stroke patients (91% ischemic) from a multicenter register,
based in the United Kingdom.
Scale Validation and Updating
SOAR was internally validated using a bootstrapping resampling
method, with reported AUROC values being the same for
both 7-day and inpatient mortality: 0.79 (95%CI: 0.78–0.80).
For predicting length of hospital stay, dichotomized at seven
days, AUROC was 0.61 (95%CI: 0.60–0.62). Although external
validation was not included as part of the derivation paper, SOAR
has been subsequently assessed in independent datasets in five
studies (98–103). Four studies assessed the scale’s performance
for predicting early mortality (inpatient, 7-day, discharge, and
90-day). Three found SOAR to have fair discriminatory power,
and one, good. One study applied the scale for prediction
of length of hospital stay. Discrimination was not formally
assessed, however the authors reported that SOAR scores were
significantly associated with the outcome (100).
Three external validation studies additionally aimed to
improve the scales predictive performance by adding new
variables. The modified SOAR (mSOAR) added stroke severity
(NIHSS) (98). When compared to SOAR, mSOAR was found
to have superior discriminatory power: AUROC of 0.83
(95%CI: 0.79–0.86) vs. 0.79 (95%CI: 0.75–0.84). Noteworthy,
performance was assessed in the mSOAR derivation set.
Nonetheless, the finding was confirmed in an independent
Chinese patient sample: AUROC of 0.78 (95%CI: 0.76–0.81)
and 0.79 (95%CI: 0.77–0.80) for discharge and 90-day mortality,
respectively, compared to 0.72 (95%CI: 0.70–0.75) and 0.70
(95%CI: 0.69–0.72), respectively, with higher estimates reported
for mSOAR. The remaining two updates of SOAR included
adding admission blood glucose levels (SOAR-G) and admission
sodium (SOAR-Na) (101, 103). Both concluded that the
original and revised scales performed well, however without
evidence of the latter offering a significant improvement in
discriminatory power.
Critical Appraisal and Clinical Application
Reviewing the SOAR derivation study, we noted that the authors
intended to select predictors for multivariable analysis based on
univariable associations. However, as all candidate predictors
were found to be significantly associated with the outcome,
using this approach would not have influenced the results. In
this case, what seems to be a greater issue, is that sex was
not included in the final model, despite the significance of its
association in both univariable and multivariable analyses. Risk
of bias was increased by excluding all patient with missing data
from the study, as well as by not accounting for effects of
administered treatments.
For implementation in clinical practice, the simplicity of
SOAR appears a major advantage, including easily accessible
information on only four variables. Adding NIHSS is the
only attempted modification that has significantly improved
scale performance. In many centers, where the measure is
not routinely used, this will introduce an additional challenge,
yet it is worth considering that stroke severity has been
consistently found to be associated with post-stroke outcomes.
Calculation of mSOAR can be aided by use of an online
tool (104).
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Stroke Prognosis Instrument (SPI)
Scale Content and Development
SPI was developed to predict risk of stroke or death within
2 years of TIA or minor stroke (105). A score ranging from
0 to 11 is calculated based on five variables: age, history of
diabetes and coronary heart disease, acute hypertension, and
presentation (TIA or minor stroke). This score assigns patients
to one of three risk groups: low (0–2 points), medium (3–6
points), and high (7–11 points). The scale was developed based
on survival analysis, specifically using a Cox proportional hazards
model. The derivation cohort included 142 patients, who had
undergone carotid ultrasonography in a United States tertiary
care hospital. Based on data from this sample, an initial SPI
score was developed, including only three variables: age, diabetes,
and hypertension.
Scale Validation and Updating
In the derivation study, the SPI score was assessed based on its
ability to accurately stratify patients according to risk of stroke
or death, using data from the development sample, as well as in
an independent Canadian cohort, including 330 patients. In the
derivation set, the results showed that 3% of patients estimated
as being at low risk had a subsequent stroke or died within 2
years of the initial neurovascular event, while the incidence for
patients assigned to the medium risk group was 27%, and for
those in the high-risk group 48%. For the validation cohort, the
incidence of stroke and death were 10, 21, and 59%, for the 3
risk groups respectively. To ameliorate decreased performance
estimates in the external set, two more variables were added to
the scale, differentiation between a TIA and a minor stroke, and
a history of coronary heart disease.
The authors of SPI subsequently externally validated the final
scale in four independent cohorts, and used one of these cohorts
to develop a modified version of the scale (106). SPI-II was
derived based on data from 525 female patients, who participated
in the Women’s Estrogen for Stroke Trial (107). In addition to
the original variables, SPI-II incorporates history of congestive
heart failure and prior stroke, with total scores ranging from 0
to 15. Data from three cohorts, with a total of 9,220 patients,
were used in a pooled analysis to estimate the AUROC values for
both scales, concluding that SPI-II (0.63; 95%CI: 0.62–0.65) had
superior discriminatory power to SPI-I (0.59; 95%CI: 0.57–0.60).
SPI-II has been subsequently externally validated in two
studies (108, 109). The first found that for prediction of both
stroke and death at 1 year, SPI-II had poor discriminatory power
(0.62; 95%CI: 0.61–0.64), which further decreased when limiting
the outcome measure to recurrent stroke (0.55; 95%CI: 0.51–
0.59). In the second study, groups identified as medium and high
risk were combined, and the scale applied to predict 3-month
recurrence of ischemic events. Here, the scale was found to have
an AUROC of 0.55 (95%CI: 0.41–0.69).
Critical Appraisal and Clinical Application
The SPI derivation study had a high risk of bias. Exclusion criteria
for study participation included previous stroke and any missing
data on variables of interest. As a result, close to 60% of the
baseline sample were not included in the analyses, leaving an
insufficient number of participants relative to the number of
predictors that were investigated. All of these predictors were
categorized. Distinguishing between TIAs, minor strokes, and
stroke has potential for interobserver variability. All candidate
predictors were included in analysis, however forward selection
method was used.
In relation to assessing scale performance, we noted that
neither discrimination nor calibration were assessed in the SPI
derivation study. The chosen validation cohort also differed
from the derivation set in that some predictors were measured
in alternative ways, and patients with previous strokes were
included. The latter introduced an additional problem, as a
history of cerebrovascular events was found to be significantly
associated with the outcome. However, as this could not
be investigated in the derivation set, the variable was not
incorporated as a predictor. The he final SPI score seemed to be
derived on the basis of a partially erroneous process of rounding
up variable coefficient values.
SPI-II is also at high risk of bias, using data from a female-
only patient sample. Although the revised scale was found
to have significantly increased discriminatory power compared
to the original, it was nonetheless poor, as confirmed in
subsequent validation studies. The scale’s predicted outcome is
also problematic, creating a highly heterogenous risk group. On
one hand, with a highly diverse range of possible scenarios,
identifying a set of predictors both necessary and sufficient
for accurate outcome prognosis seems extremely difficult. On
the other hand, for clinicians, and particularly for patients,
identifying that one belongs to a high-risk group seems of limited
value, when this can indicate increased likelihood of anything
from a minor stroke with no residual disability to death.
Stroke Thrombolytic Predictive
Instrument (S-TPI)
Scale Content and Development
S-TPI was developed to assist clinicians in predicting the
outcome of ischemic stroke patients following intravenous IV-
tPA (110). Two logistic regression models were created: one for
prediction of good outcome (mRS<2) and one for prediction
of catastrophic outcome (mRS>4), at 3 months. In addition
to IV-tPA treatment, the former model included the following
variables: age, initial systolic blood pressure, diabetes, sex,
baseline NIHSS score, prior stroke, and symptom onset to
treatment time; as well as interaction terms: treatment with blood
pressure, sex, prior stroke, and onset to treatment time, and
age with NIHSS. For prediction of catastrophic outcome, the
model consisted of considerably fewer inputs: age, NIHSS, serum
glucose and ASPECTS score, the latter treated as an optional
variable, with inclusion subject to availability. The models
were derived using a combined dataset from five randomized
clinical trials of IV-tPA, involving 1983, 1967, and 1883 patients
(depending on the model), out of an initial cohort of 2184.
Scale Validation and Updating
The models were internally validated using a bootstrapping
method, creating development and independent test datasets.
In the latter, AUROC values were 0.77 [interquartile range
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(IQR): 0.76–0.78] and 0.76 (IQR: 0.75–0.78), for prediction of
good outcome and catastrophic outcome without ASPECTS,
respectively. Calibration was graphically assessed through
plotting mean predicted vs. observed rates of patient outcomes
across quintiles, and was concluded to be excellent.
S-TPI was subsequently externally validated in three studies
(111–113). Two studies assessed discriminatory power based on
AUROC, finding the scale to have fair to good performance for
both good and catastrophic outcomes. Calibration curves were
investigated in all three studies. In each case, S-TPI was found
to overestimate the likelihood of a good outcome, particularly
at higher levels of observed probabilities. In relation to a
catastrophic outcome, findings were mixed, two studies reported
the scale to underestimate the likelihood of this outcome, while
the third concluded the opposite. One of the studies undertook
recalibration of the scale and further added two variables for
prediction of good outcome, signs of infarction on brain scan
and serum glucose level. The authors reported this improved the
scales discriminatory power (AUROC of 0.77 vs. 0.75) (112).
In contrast, the group that developed S-TPI sought to
simplify the scale by reducing the number of predictors, with
an aim to makes its implementation in routine clinical practice
more feasible (114). The process involved removing interaction
terms with limited external supporting evidence, removing the
ASPECT score, and exploring the use of simpler stroke severity
measures. A total of nine models were generated through logistic
regression, for prediction of three outcome levels: mRS<2,
mRS<3, and mRS>4. Results from apparent validation showed
that AUROC values for all models ranged from 0.75 to 0.80.
External validation was performed for models predicting mRS<2
and mRS<3, with findings indicating comparable discriminatory
power as in the derivation set. The authors concluded that
reducing model components did not lead to a substantial
deterioration in performance. We have not identified any further
publications externally validating the simplified S-TPI models.
Critical Appraisal and Clinical Application
Risk of bias in the derivation paper was increased by use of data
from randomized control trials. Inclusion and exclusion criteria
for such trials typically lead to recruiting a highly selective group
of participants, thus decreasing the generalizability of scales
developed based on their data. In addition, it seemed that trial
investigators were not blinded to predictors (with the exception
of use of IV-tPA vs. placebo) when assessing the outcome. Finally,
although patients with missing data were not excluded from the
derivation study outright, lack of data imputation would have
led to participants being excluded from particular analyses, when
they had no data for one or more of the variables used.
In view of scale implementation, it is important to note that
individual patient outcome predictions were to be estimated
automatically using a computer system, with an open-access
version of the instrument also published online. The latter is
however no longer available. With no presentation of an easily
calculable risk score, estimating probabilities of patient outcomes
would be a challenging task for clinicians, particularly taking into
account the complexity of the S-TPI models. Despite the effort
to simplify the scale, its use would nonetheless require applying
the regression model formulae itself. There also seems to be no
clear indication of which version of the multiple S-TPI models
is the best candidate for implementation. Overall, it appears
more evidence of predictive performance is needed before the
simplified models can be considered for clinical use, as well as
an easily-applicable scoring system.
Totaled Health Risks in Vascular Events
Stroke (THRIVE)
Scale Content and Development
The THRIVE scale was originally developed with an aim
to support identification of patients who may benefit from
endovascular stroke treatments, in terms of 3-month functional
outcome and risk of death (115). The scale includes five clinical
variables: age, stroke severity, and history of hypertension,
diabetes mellitus and atrial fibrillation. On their basis, an integer
score is calculated ranging from 0 to 9, with higher scores
associated with a greater probability of a poor outcome. The scale
was developed using logistic and ordinal regression models. The
derivation cohort included participants of the MERCI and Multi
MERCI trials of mechanical thrombectomy, with a total of 305
ischemic stroke patients (116, 117).
Scale Validation and Updating
The derivation paper reported results of apparent validation for
prediction of good outcome (mRS<3), finding that the final
prognostic model had an AUROC of 0.71. The THRIVE score,
developed based on estimated odds ratios for each predictor, was
assessed in terms of its association with the percentage of patients
with a particular outcome. A good outcome was observed in
64.7% of patients with a score of 0–2 and in 10.6% of cases with
a score of 6–9. Reported mortality rates were 5.9 and 56.4% for
patients with low and high THRIVE scores, respectively.
There have been 16 subsequent studies externally validating
THRIVE. These involved patient groups receiving intra-arterial
therapy, intravenous thrombolysis, and no acute treatments, and
focused on a number of different outcomes – good functional
outcome, poor outcome, risk of hemorrhagic transformations,
infarct size, and even pulmonary infection (44, 118–132). The
majority of studies aimed to predict multiple outcomes, and 15
assessed the scales predictive performance in terms of AUROC
values, typically alongside other estimates. Seven studies found
the discriminatory power to be either poor or fair, depending on
the outcome, four reported it to be poor for all used outcomes,
three to be fair, and only one study found the performance to be
good, specifically for prediction of mortality rates.
With an aim to improve the scale’s predictive performance, a
revised version was developed, the THRIVE-c Calculation (133).
The modified tool includes the same variables as the original
scale, with age and NIHSS score entered as continuous rather
than categorized variables. The derivation study reported results
of apparent, internal (split-sample) and external validation, with
AUROC values ranging from 0.77 to 0.80 for prediction of poor
outcome. In the overall study cohort, THRIVE-c was found to
have significantly superior predictive performance compared to
the original THRIVE score (0.79, 95%CI: 0.78–0.79 vs. 0.75,
95%CI: 0.74–0.76). THRIVE-c has been subsequently externally
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validated in a Chinese population of patients receiving IV-tPA
(134). The scale was used to predict symptomatic hemorrhage,
poor functional outcome and mortality, with reported AUROC
values of 0.70, 0.75, and 0.81, respectively.
Critical Appraisal and Clinical Application
Our critical appraisal of the THRIVE derivation study indicated
issues with each of the assessed aspects, either due to
methodological quality or incomplete reporting. The derivation
set consisted of participants recruited to a clinical trial, thus
leading to participation of a selective group of subjects. Moreover,
the final sample size andmethod of handlingmissing data seemed
unclear. In relation to input variables, the initial set of candidate
predictors appeared limited, omitting a number of factors
found to be associated with functional outcome in previous
research. Inclusion of specific chronic diseases in multivariable
analysis was based on significance of associations in univariable
analysis. Three factors, age, stroke severity and success of vessel
recanalization, were included in multivariable analyses outright,
and all were found to be independently associated with the
outcome. It is however unclear why vessel recanalization was
not incorporated into the final THRIVE scale. There was also
no report of how cut-offs were determined for the derived
THRIVE score.
Assessment of scale performance in the derivation study
was limited to apparent validation. Moreover, discriminatory
power was tested only for the model predicting good outcome;
it was not assessed for the model predicting mortality or for
the derived THRIVE score. Although the scale has undergone
extensive external validation since its development, findings from
these studies do not seem to support a favorable judgement
on the scale’s prognostic performance. THRIVE-c appears to
be a superior alternative, yet up-to-date we have found only
one independent validation study assessing the scale’s predictive
ability. In view of use in routine clinical practice, inclusion of
relatively few variables, based on information typically available
in an acute setting, is a relevant advantage of THRIVE. Score
calculation can additionally be aided be use of an online tool
(135). However, existing evidence on predictive ability does not
seem to merit implementation.
DISCUSSION
There are many prognostic tools available for use in acute stroke
settings. We have reviewed a selection of these and common
themes emerge. Our primary interests were methodological
quality of derivation, subsequent external validation and scale
usability in routine clinical practice. Across 10 primary derivation
studies of better-known scales, we identified potential sources
of bias in each. However, it is the results of external validation
studies that allow us to conclude on the scales prognostic
value and applicability. We found that all scales, but one, were
externally validated.
While there was a range of prognostic accuracies reported,
most scales had properties that would be considered “acceptable.”
This is perhaps not surprising as the scales tended to measure
the same concepts of demographics, comorbidity, initial stroke
severity and pre-stroke functional status. Where scale developers
have tried to add additional elements to these core predictors, the
gain in predictive power has been limited. However, most scales
have been developed with a biomedical focus and it is plausible
that other less traditional factors could improve utility of the
scales, for example incorporating measures of frailty, resilience,
provision of rehabilitation services and social support, or the
clinician’s clinical gestalt.
Based on our literature search, we identified the highest
number of external validation studies for THRIVE. Yet results
indicated a level of predictive performance insufficient to merit
the scale’s use in a clinical setting. Our critical appraisal may
partly explain this, identifying concerns relating to all aspects
of THRIVE’s derivation process. Four other scales, ASTRAL,
DRAGON, iScore, and SOAR, have also been validated in
multiple independent datasets. For all, findings suggested a level
of predictive ability that would merit implementing the scales
in clinical practice. Moreover, one study reported ASTRAL and
DRAGON to predict patient outcomes more accurately than
clinicians (46). Although evidence regarding the performance
of other scales included in this review seemed insufficient to
reach firm conclusions, a number of these tools were derived
with relatively low risk of bias, and future research is likely to
confirm their prognostic value. These include PLAN, SNARL, S-
TPI, as well as updated scale versions: MRI-DRAGON, iScore-r
and mSOAR.
For a number of reasons, it is challenging to directly compare
the reviewed prognostic tools, and we have deliberately chosen
to avoid naming a single preferred tool. Firstly, studies assessing
more than one scale as part of an external validation process
are relatively uncommon. When conducted, findings are often
difficult to interpret, small differences in predictive ability
between scales may arise from the superiority of one over
another, but they could also be attributed to an incidentally
greater similarity between the validation set and the derivation set
of the scale found to perform best. Secondly, although satisfactory
predictive ability is essential for a scale to be clinically useful, it is
not sufficient. A number of other factors need to be considered,
including feasibility in routine clinical practice, the relevance
of the predicted outcome to the specific context, and whether
applying the tool improves clinical decision-making, patient
outcomes or cost-effectiveness of services (136). To help answer
these questions, it is necessary to conduct impact studies, a
stage in prognostic research that to our knowledge none of the
described scales have yet reached.
Our focused literature review has strengths and limitations.
We recognize that there have been many high quality systematic
and narrative reviews of stroke prognosis scales (10, 137).
We hope that our review offers a novel focus. We have
appraised relevant stroke scales against each other; very few
derivation papers have done this, despite its importance when
choosing which scale to use. Additionally, we have followed the
PRISMA systematic review guidelines (9) when designing and
completing our study and based our appraisal on the CHARMS
checklist (16). Our intention was not to offer a comprehensive
review, rather we choose exemplar scales that featured in high
impact journals and so by implication would be amongst the
best known in the clinical community. In our assessment of
feasibility we identified clinical and radiological features that
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may be challenging to assess in the acute setting (63, 138). Our
focus was routine stroke practice (139) and our comments on
feasibility may not apply to specialist stroke centers. It takes
time for scales to become established and our review did not
include recently published scales, for example those designed to
inform thrombectomy decisions (140). However, the literature
describing these scales is increasing rapidly and soon there may
be sufficient validation studies.
We used data from our focused literature review to compare
long-term stroke prognosis scales. We found many scales with
similar content and properties. Although development of the
scales did not always follow methodological best practice, most
of these scales have been subsequently validated. Rather than
developing new scales, prognostic research in stroke should now
focus on implementation and comparative analyses.
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